Novartis Acquires Kate Therapeutics for Gene Therapy

Novartis has acquired Kate Therapeutics, a company focused on gene therapies for inherited neuromuscular diseases, in a deal worth up to $1.1 billion. This acquisition includes preclinical programs targeting Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1. Kate’s DELIVER platform, which enhances the precision of gene therapy delivery using evolved AAV capsids, aligns with Novartis’ commitment to addressing unmet needs in neuromuscular disorders.

With the addition of Kate’s cutting-edge technology, Novartis strengthens its position in gene therapy and neuroscience innovation, opening new avenues for safer and more effective treatments for these challenging genetic diseases.